Black Diamond Therapeutics (BDTX) vs Humacyte (HUMA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Black Diamond Therapeutics (BDTX) has outperformed Humacyte (HUMA) over the past year, losing 54.6% versus a loss of 73.5%. Over five years, BDTX leads with a -77.9% price change compared with -95.6% for HUMA. Humacyte is the larger company by market cap ($124.2 million vs $103.7 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BDTX | HUMA |
|---|---|---|
| Share price | $1.81 | $0.4471 |
| Market cap | $103.72M | $124.20M |
| 1-day change | -1.09% | -5.34% |
| YTD return | -25.51% | -53.48% |
| 1-year return | -54.64% | -73.54% |
| 5-year return | -77.87% | -95.63% |
| EPS (TTM) | $-0.75 | $-0.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.94 | $1.90 |
| 52-week low | $1.60 | $0.4367 |
| Distance from 52-week high | -63.36% | -76.41% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +452.49% | +264.57% |
| Average volume | 624.32K | 6.23M |
| Shares outstanding | 57.30M | 277.80M |
| Employees | 21 | 184 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BDTX has outperformed HUMA by 18.9 percentage points over the past year.
About Black Diamond Therapeutics
BDTX stock →Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 21 employees
About Humacyte
HUMA stock →Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 184 employees
BDTX vs HUMA FAQ
Which is bigger, Black Diamond Therapeutics or Humacyte?
Humacyte (HUMA) is larger, with a market capitalization of $124.20M compared with $103.72M for Black Diamond Therapeutics (BDTX).
Which stock has performed better over the past year, BDTX or HUMA?
BDTX returned -54.64% over the past 12 months, compared with -73.54% for HUMA (price return, excluding dividends). Past performance does not predict future results.
Are Black Diamond Therapeutics and Humacyte in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.